Introduction
============

Majority chronic vascular diseases, including atherosclerosis, aneurysms, diabetic angiopathy and proliferative retinopathy as well as fibrotic vascular diseases, harbor unique and common degenerative insults^[@bib1]--[@bib6])^. For example, atherosclerotic vessels frequently accompany dysfunction of the vascular endothelial cells (ECs), accumulation of cholesterol-enriched cellular apoptotic bodies, remodeling of the extracellular matrix (ECM) and breakdown of elastic lamella^[@bib2])^. Although the deposition of cholesterol is unique to atherosclerotic diseases, the endothelial dysfunction and ECM remodeling are frequently detected in other vascular diseases, such as diabetic angiopathy and vascular fibrosis. In general, vascular degenerations are driven by chronic inflammatory responses and accompanying reactive oxygen species (ROS)-mediated oxidative stress^[@bib7])^; thus, many researchers have tested anti-oxidative agents in clinical trials. Unfortunately, these antioxidative trials have thoroughly failed to reverse chronic vascular diseases^[@bib8])^, although they were effective in acute inflammation, such as the acute phase of stroke^[@bib9])^. Therefore, it is necessary to investigate how blood vessels shift toward degenerative status in chronic disease. In this regard, growing evidence suggests that the calpain proteolytic systems, comprised of Ca^2+^-dependent intracellular proteases and a calpain endogenous inhibitor, critically contribute to degenerative vascular disorders. Calpains can be potentiated in the presence of pathophysiological stressors, such as inflammatory cytokines, growth factors, bioactive lipids and hypoxic stimulus^[@bib10],\ [@bib11])^. As a result, dysregulation of these systems might be responsible for the vascular disorders noted above. In this review article, we discuss the current achievements in understanding the pathophysiology of degenerative vascular disorders, with a particular focus on the calpain proteolytic system.

Vascular Calpain Systems
========================

Calpains comprised of 15 homologues in mammals can be categorized as conventional and unconventional isozymes. Conventional calpains consist of two ubiquitous isozymes, calpain-1 and -2, which require micromolar and millimolar levels of Ca^2+^ for half-maximal activation, respectively^[@bib12]--[@bib14])^. These ubiquitous isozymes are comprised of heterodimers containing a common regulatory subunit, *CAPNS1*, and subtype-specific large subunits, *CAPN1* and *CAPN2*, which function as the catalytic subunits of calpain-1 and -2 isozymes, respectively^[@bib12]--[@bib14])^ (**[Fig. 1](#F1){ref-type="fig"}**). Conventional calpains are localized to the majority of vascular systems, including veins^[@bib15])^, arteries^[@bib16])^ and capillaries^[@bib17])^, and are also expressed in ECs^[@bib16],\ [@bib18])^, vascular smooth muscle cells (VSMCs)^[@bib19])^ and adventitial fibroblasts^[@bib20])^. In addition to the vascular component cells, calpains are localized to immune cells^[@bib21],\ [@bib22])^, which can be recruited into blood vessels in response to inflammatory insults. In addition to the conventional calpain isozymes, calpastatin, an endogenous calpain inhibitor, colocalizes with the proteases, and negatively regulates their proteolytic activity^[@bib12]--[@bib14])^. It was reported that deficiency of the *Capn1* gene in mice resulted in normal growth with a reduction in platelet aggregation and clot retraction^[@bib23])^; therefore, calpain-1 does not play a vital role in these functions. In contrast, *Capn2*-deficient mice showed embryonic lethality between the morula and blastocyst stages^[@bib24])^. Similar to *Capn2*, deficiency of *Capns1* was embryonic lethal and accompanied by disorders in cardiovascular development^[@bib25])^. Takano *et al*. subsequently reported that conditional knockout mice, in which *Capn2* was expressed in the placenta but not in the fetus, survived to adulthood^[@bib26])^. Thus, calpain-2 is unlikely to play an essential role in cardiovascular development in the fetus.

![Vascular calpain systems. Conventional calpains are localized to the majority of the vascular component cells, including vascular endothelial cells (ECs), vascular smooth muscle cells (VSMCs) and fibroblasts. Calpain-6, a non-proteolytic unconventional calpain, is inducible in foamy macrophages in athero-prone vessels. Calpastatin, an endogenous inhibitor, colocalizes with conventional isozymes, and downregulates their proteolytic activity. PC: protease core domain, CBSW: calpain-type *β*-sandwich domain, PEF: penta-EF-hand domain, GR: glycinerich domain, C2: C2 domain, XL: XL domain, L: L domain.](jat-25-1-g001){#F1}

In general, physiological substrates of conventional calpains are hard to predict, because the proteases do not strictly recognize unique consensus amino acid sequences or structural motifs in their substrates. Earlier enzymatic investigations reported that conventional calpains post-translationally proteolyze a variety of substrates, including the focal adhesion proteins talin^[@bib27])^ and vinculin^[@bib28])^, leading to alterations in cell motility and morphology. Furthermore, the calpain-dependent post-translational regulation of signaling molecules such as focal adhesion kinases^[@bib29])^, protein kinase C^[@bib30])^ and inhibitor of *κ*B (I*κ*B)^[@bib31],\ [@bib32])^ have been described previously. It was documented that conventional calpains proteolytically degrade the EC-derived angiostatic peptide vasohibin-1 in tumor cells^[@bib33])^. Recently, we identified VE-cadherin, an inter-endothelial adhesion molecule^[@bib34])^, and suppressor of cytokine signaling 3 (SOCS3), an endogenous inhibitor of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) cytokine signaling^[@bib35])^ as substrates of the calpain system. These data suggest that conventional calpains recognize diverse substrates and modify multiple signaling cascades in cells, and it is suspected that their impact on cellular functions is dependent upon cell type or environmental factors, such as the type of inducer. Please refer to the following excellent reviews for extensive reviews of the molecular basis of conventional calpains^[@bib12]--[@bib14])^.

In addition to conventional isozymes, 13 species of calpain catalytic subunit have been identified in mammals. These unconventional isoforms are further categorized into ubiquitous and tissue-specific forms according to their tissue localization in vertebrates^[@bib12]--[@bib14])^. Compared with the conventional isoforms, the roles of the unconventional isoforms in vascular regulation have been less extensively investigated, probably because of their low expression in the vasculature. Indeed, our preliminary data showed that the expression levels of unconventional calpains in murine normal healthy aorta are much lower in comparison with those of *Capn1, Capn2, Capns1* and *Cast* (our unpublished observations); nevertheless, it is suspected that certain unconventional isozymes can be potentiated under pathophysiological conditions. For instance, calpain-6 is induced in foamy macrophages in response to inflammatory stimuli during atherogenesis^[@bib36])^, whereas this molecule was reportedly localized to fetal skeletal muscle, cartilage and heart^[@bib37])^ as well as the placenta in adults^[@bib38])^ but not to blood vessels during normal physiological status. This subtype appears to lack proteolytic activity, as the cysteine residue in its active core is substituted with lysine^[@bib12]--[@bib14])^ (**[Fig. 1](#F1){ref-type="fig"}**). Tonami *et al.* identified that the deletion of *Capn6* in mice promoted the development of embryonic skeletal muscle^[@bib37])^. Furthermore, calpain-6 was induced during the regeneration of skeletal muscles in adult mice after cardiotoxin-induced degeneration, and *Capn6* deficiency accelerated skeletal-muscle regeneration in mice^[@bib37])^; however, the role of calpain-6 in the physiological regulation of vascular systems is currently poorly understood.

Calpain-10 is ubiquitously expressed and is associated with apoptosis in pancreatic islet cells^[@bib39])^, mitochondrial dysfunction^[@bib40])^, insulin secretion from pancreatic islets^[@bib41],\ [@bib42])^, and the oxidative utilization of glucose in skeletal muscle^[@bib43])^. *Capn10* deficiency in the SM/J mouse strain ameliorated insulin resistance and reduced blood glucose levels^[@bib44])^. Furthermore, a genome-wide analysis has shown that a *CAPN10* polymorphism is involved in insulin resistance, dyslipidemia, and high free fatty acid levels in a Japanese population^[@bib45])^; obesity in a Scandinavian population^[@bib46])^; and free fatty acid levels in a Finnish population^[@bib47])^. It is likely that genetic variation in the *CAPN10* locus confers higher cardiovascular disease risk to type 2 diabetes mellitus patients^[@bib48])^. Therefore, calpain-10 might induce diabetic angiopathy through its diabetogenic actions, whereas the direct role of this molecule in vascular regulation is unknown.

Contribution of Calpain Proteolytic Systems to Degenerative Vascular Disorders
==============================================================================

Atherosclerosis and Aneurysmal Diseases
---------------------------------------

Atherosclerosis is a vascular disease characterized by the intimal thickening of systemic arteries, including the coronary and cerebral arteries as well as the aorta^[@bib49],\ [@bib50])^. Vulnerable and occlusive atherosclerotic plaques can lead to lethal cardiovascular events, including myocardial infarction and stroke, two primary causes of morbidity and mortality worldwide. Because many pathogenic cues contribute to atherogenesis^[@bib50])^, it is difficult to precisely define the cause of atherosclerosis; however, the majority of investigations are based on the hypothesis that ROS-mediated oxidative stress in atherosclerotic lesions induces various inflammatory elements, such as endothelial adhesion molecules (e.g. intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin), inflammatory cytokines and chemokines, through redox-sensitive transcription factors^[@bib50])^. The overexpression of adhesion molecules in ECs facilitates leukocyte adhesion to ECs and monocyte chemoattractant protein-1 potentiates cellular motility in monocytes/macrophages, thereby accelerating the infiltration of these cells into lesions. Recruited macrophages incorporate low-density lipoprotein (LDL) cholesterol through micro/macro pinocytosis and phagocytosis pathways as well as scavenger receptor-mediated endocytosis^[@bib51])^. Internalized endocytic vesicles fuse with lysosomes; accordingly, the enclosed lipoproteins are degraded through lysosomal digestion. After lysosomal degradation, acyl-coenzyme A: cholesterol acyltransferase 1 converts free cholesterol to highly hydrophobic cholesterol esters, thereby forming lipid-enriched foam cells^[@bib52])^. In addition to the cholesterol deposition in macrophages, immune responses in immunocompetent cells including T cells, B cells and mast cells in the lesions orchestrate atherogenicity^[@bib53])^. For instance, type 1 and type 2 T-helper cells polarize macrophages toward M1 and M2 subsets, respectively^[@bib54])^. It was reported that M1 macrophages largely contribute to the progression of atherogenesis through its pro-inflammatory ability. Furthermore, inflammasomal production of interleukin (IL)-1*β* reportedly facilitates development of atherosclerotic lesions^[@bib55])^; thus, innate immunity as well as adaptive immunity can modify the atherosclerotic vascular inflammation. We have previously reported that *Capn2, Capn6* and *Capn9*, but not other family members, are induced in the pro-atherogenic aortae of high cholesterol diet-fed *Ldlr*^−/−^ mice^[@bib36])^. Among these calpain species, conventional calpain-2 is induced in response to oxidized or enzymatically-modified LDL or its component lysophosphatidylcholine, and is abundant in ECs in mouse and human atheromas^[@bib34])^. The calpain inhibitors calpeptin or ALLM (N-acetyl-L-leucyl-L-leucyl-L-methioninal) appear to prevent pro-atherogenic barrier dysfunctions in ECs, and reduce the recruitment of circulating monocytes into atherosclerotic lesions; thus, the administration of these inhibitors to high cholesterol diet-fed *Apoe*^−/−^ or *Ldlr*^−/−^ mice suppresses the development of atherosclerotic lesions. In these cases, barrier dysfunction is caused by the calpain-2-induced proteolysis of VE-cadherin, because VE-cadherin promotes homophilic adhesion between ECs, thereby forming an interendothelial barrier^[@bib56])^. Subramanian *et al.* also noted that atherosclerotic lesion progression in angiotensin II-infused *Ldlr*^−/−^ mice was impaired by the calpain inhibitor BDA-410^[@bib57])^. Transgenic overexpression of calpastatin significantly attenuated angiotensin II- or hypercholesterolemia-induced atherosclerotic development in *Ldlr*^−/−^ mice^[@bib58])^. Furthermore, myeloid calpain-1 or leukocyte calpain-2 were involved in angiotensin II-induced atherosclerosis^[@bib58])^. In this case, calpain inhibition reduced the motility, mitosis and nuclear factor-*κ*B (NF-*κ*B)-dependent inflammatory responses in isolated macrophages. Collectively, it is likely that conventional calpains are involved in the pro-atherogenic regulation of EC and macrophages.

In addition to the pro-atherogenic actions of the conventional calpains, we recently identified the contribution of unconventional calpains to the pathogenesis of atherosclerosis^[@bib36])^. Indeed, *Capn6* ablation prevented the development of atherosclerotic lesions in mice, whereas *Capn9* knockout did not affect the phenotype. Calpain-6 is localized to macrophages, but not to other vascular component cells in advanced human and murine atheromas. Consistently, bone marrow transplantation experiments have demonstrated that myeloid *Capn6* is responsible for atherogenesis. Calpain-6 in macrophages is inducible in response to inflammatory cytokines such as tumor necrosis factor-*α* (TNF-*α*), and directly binds to CWC22, an essential loading factor for the exon-junction complex (EJC). CWC22 escorts the EJC to the nucleus, which is necessary for spliceosome-driven mRNA splicing. The efficiency of mRNA splicing was reduced after silencing CWC22^[@bib59])^; thus, CWC22 is indispensable for mRNA splicing. The binding of calpain-6 with CWC22 in the cytoplasm prevented the nuclear translocation of CWC22. Accordingly, the splicing efficiency of their target genes, including Rac1, was decreased in the presence of calpain-6, which conferred atherogenicity to foamy macrophages. Rac1 is a negative regulator of the pinocytosis pathway; thus, the impaired nuclear translocation of CWC22 by calpain-6 augments the pinocytotic uptake of native LDL in macrophages. Importantly, the ablation of calpain-6 substantially decreased pinocytotic activity in macrophages in murine atherosclerotic lesions^[@bib36])^. Immunohistochemistry of human aortic atheromas showed that the nuclear localization of CWC22 was diminished in macrophages in advanced atheromas but not in cells of mild atherosclerotic lesions, while calpain-6 was upregulated in macrophages in advanced atheromas^[@bib36])^. Thus, the calpain-6-induced disruption of CWC22/EJC in macrophages translates to human atherosclerotic lesions. A previous review articles have further details of calpain-mediated regulation of atherosclerosis^[@bib10])^ and pro-atherogenic cholesterol handling in macrophages^[@bib60])^.

Abdominal aortic aneurysm, a representative atherosclerotic disease, is a major cause of cardiovascular death and the tenth leading cause of death in men over 65 years of age in western countries^[@bib61])^. Excessive oxidative stress in atheroprone arteries facilitates the accumulation of matrix metalloproteinases (MMPs) and subsequent remodeling of vascular tissues, which is sometimes a threshold process in aneurysmal diseases^[@bib62],\ [@bib63])^. Indeed, macrophage- and vascular cell-derived MMPs-9 and -12 are considered major exacerbators of aneurysmal diseases^[@bib64],\ [@bib65])^, because they break down vascular structures, including the elastic lamellae and basement membrane, which leads to vascular dissection^[@bib62],\ [@bib63])^. Previous proteomic analyses demonstrated the contribution of calpain-2 to aortic aneurysms in Marfan syndrome^[@bib66])^; thus, it was suspected that conventional calpains cause atherosclerotic aortic aneurysms. Indeed, the pharmacological intervention of conventional calpains by BDA-410 ameliorated aortic dissection in angiotensin II-infused *Ldlr*^−/−^ mice, concomitant with the reduction of MMP12, IL-6 and MCP-1 levels in the vessels^[@bib67])^. In contrast, the myeloidspecific transduction of calpastatin or deficiency of calpain-1 as well as the macrophage-specific deficiency of calpain-2 had no effect on aneurysmal formation in angiotensin II-induced *Ldlr*^−/−^ mice, while deficiency of conventional calpains significantly attenuated the development of atherosclerotic lesions^[@bib68])^. Thus, it is suspected that vascular component cells, such as ECs or VSMCs, or other immune cells are involved in calpain-dependent aortic aneurysms.

Diabetic Angiopathy
-------------------

Type 1 and type 2 diabetes mellitus are chronic metabolic diseases caused by impaired insulin production in the pancreas and systemic insulin resistance, respectively, leading to the dysregulation of plasma glucose levels. It is well known that hyperglycemia results in vascular disorders, including diabetic retinopathy and nephropathy, which are the major complications of this disease^[@bib5])^. Among the vascular component cells, dysfunction of ECs is primarily responsible for hyperglycemia-induced angiopathy^[@bib69])^. While the exact mechanisms underlying these endothelial disorders are still unclear, the majority of studies have been based on the context that endothelial disorders are caused by excessive oxidative stress in blood vessels^[@bib70])^. Indeed, it was reported that the exposure of ECs to high glucose conditions resulted in the elevation of ROS levels^[@bib71])^. Furthermore, endothelial-dependent vasodilation, which is measured as an index of endothelial integrity, was reduced in diabetic animals, and was recovered by the administration of antioxidants^[@bib72])^. Indeed, the elevation of ROS levels in blood vessels was detected in diabetic mice and human diabetic patients^[@bib73],\ [@bib74])^, suggesting a pivotal role of ROS signaling in the pathogenesis of diabetic endothelial disorders. It was previously reported that the major source of ROS in blood vessels is NADPH oxidase, xanthine oxidase and uncoupled nitric oxide (NO) synthase (NOS) as well as mitochondrial respiration^[@bib75])^. Uncoupled eNOS, which generates superoxides instead of NO, as well as xanthine oxidase, and NADPH oxidase are largely responsible for ROS production even in diabetic vessels^[@bib76],\ [@bib77])^. It was reported that physiological NO production in ECs was dependent upon conventional calpains. Youn *et al.* noted that the vascular endothelial growth factor (VEGF)-induced production of NO in cultured ECs was reduced by calpain inhibitors ALLN (N-acetyl-leucyl-leucyl-norleucinal) or calpeptin^[@bib78])^. VEGF facilitates calpain translocation to the plasma membrane and formation of the molecular complex together with ezrin; as a result, the calpain-associated molecular complex potentiates the phosphorylation of AKT, AMP-dependent kinase and endothelial NOS (eNOS)~s1179~, which is necessary for VEGF-induced NO production and subsequent angiogenic responses in ECs. Conversely, calpain-induced defects of endothelial NO systems have been also proposed. Cell-based experiments showed that ionophore-induced calpain overactivation proteolyzed heat shock protein 90 (HSP90) as well as eNOS and neural NOS^[@bib79])^. Whereas the difference between the VEGF- and ionophore-induced NO production has not been thoroughly elucidated, Ca^2+^ overloading in cytoplasm might cause the excessive activation of conventional calpains thereby degrading unusual non-physiologic substrates including HSP90, which seems to be distinct from the physiological regulation mechanism. In addition to physiologic NO production, calpain was reportedly associated with defective NO systems in diabetes. Stalker *et al.* previously reported that inhibition of conventional calpains by ZLLal (aldehyde benzyloxycarbonylleucyl-leucinal) recovers impaired NO production and subsequent vasculitis in mesenteric venules in ZDF rats, concomitantly with the increasing association of eNOS with HSP90^[@bib80])^. Chen *et al.* reported that conventional calpains in human umbilical vein endothelial cells were activated under high glucose conditions, accompanied by a reduction of NO production and elevation of cytosolic ROS levels without altering NOS expression levels^[@bib81])^. Intriguingly, the glucose-induced changes in NO and ROS production were reversed by the transduction of calpastatin. Furthermore, aortic ROS levels were elevated in transgenic type 1 diabetic OVE26 mice, and were inhibited by calpastatin transduction. While endothelium-dependent vasodilation in diabetic OVE26 mice was blunted, calpastatin transduction improved the endothelial integrity of diabetic animals^[@bib81])^. It was also documented that siRNA against calpain-1 prevented phosphorylation of eNOS at threonine 497/495 in murine aorta and cultured ECs under the hyperhomocysteinemia/high glucose conditions thereby improving NO production and subsequent EC integrity^[@bib82])^. Thus, the overactivation of conventional calpain systems under diabetic conditions promotes dysfunctional endothelial NO systems, leading to reduction of endothelial integrity.

In addition to its defective regulation of NO signaling, the calpain-induced perturbation of prostanoid signaling has been reported as another pathogenic cue for diabetic angiopathy. Randriamboavonjy *et al.* reported that pharmacological calpain inhibition by A-705232 recovered EC-dependent vasodilation in diabetic mesenteric arteries^[@bib83])^. This recovery was dependent upon protection by prostaglandin I^[@bib2]^ synthase (PGIS) from calpain-induced degradation. While the treatment of mesenteric arteries with peroxynitrate donors impaired endothelium-dependent vasodilation even in the presence or absence of a NO scavenger^[@bib83])^, it was recovered by the calpain inhibitor calpeptin. Collectively, the overactivation of conventional calpains opposes prostaglandin I~2~ synthesis in diabetic small vessels independent of NO signaling, which might cause diabetic angiopathy.

Proliferative Retinopathy and Cancer Neovessels
-----------------------------------------------

It is well known that abnormalities of pathological neovessels in proliferative retinopathy and tumor neovessels are caused by defective angiogenic signaling in ECs. During normal physiological status, ECs rearrange their shape via oxygen sensors and hypoxia-inducible factors, including prolyl hydroxylase domain 2 and hypoxia-inducible factor (HIF)-2*α*, respectively to optimize blood flow^[@bib84])^. When the tissue becomes hypoxic, angiogenic responses are robustly activated through angiogenic mediators including VEGF-A, VEGF-C, fibroblast growth factors and angiopoietin-2. Such mediators accelerate the motility and mitosis of leading ECs (termed the tip cell) mainly through their surface receptors thereby driving endothelial tube formation. Tip cells guide the following ECs (termed stalk cells) and VEGFR2 in stalk cells is subsequently downregulated through the DLL4/NOTCH pathway to facilitate the coverage of immature vessels with pericytes^[@bib84])^. According to such stepwise vascular maturation, the physiological neovessels acquire a hierarchical network as shown in the pre-existing vasculature. Increasing evidence suggests that conventional calpain systems contribute to physiological angiogenesis. For example, Zheng *et al.* recently noted the calpain-induced acceleration of HIF-1 signals^[@bib85])^. In this case, calpain-induced the proteolysis of filamin-A, a large cytoskeletal actin-binding protein, whereby filamin-A proteolytic fragments physically interacted with HIF-1*α* to promote the nuclear localization of HIF-1*α*. However, it is noteworthy that *Capn1*-deficient mice as well as EC-specific *Capn2*-deficient mice did not exhibit the lethal vascular defects^[@bib23],\ [@bib26])^; thus, the impact of calpain-dependent angiogenesis on physiological vascular regulations is currently unclear. Please refer to an excellent review for further details of calpain-mediated physiological angiogenesis^[@bib86])^.

In contrast to the physiological neovessels, pathological neovessels, which are frequently detected in inflamed lesions (e.g. atherosclerotic lesions and diabetic retinopathy) as well as tumor tissues, exhibit an unstable and non-hierarchical structure^[@bib84],\ [@bib87],\ [@bib88])^. Although both physiological and pathological angiogenesis are similarly driven by common angiogenic cues (e.g. angiopoietin-2 and VEGF), pathological neovessels exhibit immature properties characterized by a lack of pericyte coverage, a thin extracellular matrix layer and poor inter-endothelial junctions^[@bib84])^. Because of these structural instabilities, pathological neovessels provide a major route for the recruitment of immune cells into inflamed lesions or for metastatic cancer cell emigration from primary tumor tissues, which leads to the further progression of disease. The critical difference between physiological and pathological angiogenesis is that the latter is affected by the surrounding inflammatory conditions. Interestingly, inflammatory and angiogenic signals are slightly interrelated and redundant. Indeed, several classes of proinflammatory cytokines, including TNF-*α* and IL-6, have angiogenic effects on vascular ECs^[@bib89]--[@bib91])^. Furthermore, the ablation of endothelial SOCS3, an endogenous inhibitor of JAK/STAT cytokine signals, accelerated growth factor- and cytokine-induced angiogenesis thereby aggravating cancer growth and oxygen-induced retinopathy (OIR) in mice^[@bib90])^. It was reported that conventional calpains are associated with pathological angiogenesis. Indeed, Hoang *et al.* noted that calpain inhibitors MDL 28170, PD150606, or ALLN opposed the pathogenesis of OIR in mice, and normalized the morphology of retinal vessels^[@bib92])^. Furthermore, we previously documented the contribution of endothelial calpains to pathological angiogenesis^[@bib35])^. Mechanistically, the loss of calpastatin by several growth factor classes, causes the calpain-1-induced proteolytic degradation of SOCS3, leading to VEGF-C production through excessive JAK/STAT signaling. Accordingly, calpastatin downregulation facilitates IL-6-driven angiogenic responses in ECs through the local autocrine action of VEGF-C. Similarly, the downregulation of calpastatin and SOCS3 expression is detectable in neovessels in human colon adenocarcinoma, lung adenocarcinoma and malignant astrocytoma. The EC-specific transduction of calpastatin counteracts the STAT3/VEGF-C axis and antagonizes pathological angiogenesis in allograft tumors and OIR in mice, which suppresses such diseases. Whereas pathological neovessels in these diseases lack coverage of pericytes and formation of a basement membrane, calpastatin transduction improves the maturity of neovessels. Therefore, the overactivation of conventional calpains sensitizes JAK/STAT inflammatory cascades, which converts angiogenic ECs to pathological status.

In addition to angiogenic roles in ECs, conventional calpains are associated with the metabolism of angiostatic mediators. Saito *et al.* reported that calpain in cancer cells proteolytically degraded the angiostatic peptide vasohibin-1^[@bib33])^. Vasohibin-1 synthesized in ECs can inhibit angiogenic responses by an autocrine mechanism; thus, the degradation of vashibin-1 by tumoral calpains might facilitate tumor angiogenesis.

Vascular Fibrosis and Pulmonary Hypertension
--------------------------------------------

It is well known that aging induces structural and functional changes in arteries, and is a critical risk factor for cardiovascular defects, such as hypertension and atherosclerosis^[@bib93],\ [@bib94])^. An age-associated increase in arterial wall stiffness is largely dependent upon remodeling of the ECM and vascular calcification. In general, ECM remodeling in aged arteries occurs because of increased collagen content, elastin fragmentation, and is triggered by the transformation of contractile VSMCs to a synthetic phenotype. Letavernier *et al.* reported that vascular fibrosis and hypertrophy in angiotensin II-infused mice was prevented by calpastatin transduction^[@bib95])^. Furthermore, impaired fibrogenic responses were caused by a reduction of medial MMP levels and NF-*κ*B activity. Similarly, Jiang *et al.* reported that the induction of calpain-1 in VSMCs was associated with MMP2 upregulation and subsequent ageassociated vascular fibrosis in rats^[@bib19])^. Furthermore, the overexpression of calpain-1 in rats accelerated arterial calcification as well as fibrosis in aged rats, concomitant with a reduction of osteopontin and osteonectin levels in VSMCs^[@bib96])^. Tang *et al.* reported that the transduction of calpastatin reduced VSMC proliferation and collagen synthesis thereby inhibiting restenosis induced by carotid artery ligation in mice^[@bib97])^. Thus, calpain systems contribute to the variety of fibrogenic and proliferative responses in VSMCs.

Pulmonary hypertension is a proliferative vascular disease characterized by medial thickening and severe fibrosis in the right ventricular artery thereby increasing pulmonary vascular resistance and subsequent right heart failure^[@bib98],\ [@bib99])^. Excessive proliferation of VSMCs and hypertrophy as well as the production of ECM contributes to medial hypertrophy, leading to the destruction of precapillary pulmonary arteries and a sustained elevation of pulmonary arterial pressure. Ma *et al.* previously reported that a deficiency of *Capns1* reduced both calpain-1 and -2 levels, reduced collagen synthesis and remodeling in pulmonary arterioles and the subsequent pathogenesis of pulmonary hypertension in mice^[@bib100])^. Calpain activated transforming growth factor (TGF)-*β*1 via direct proteolytic processing; thus, calpain deficiency resulted in the prevention of TGF-*β*1-induced fibrogenic responses in VSMCs. They also reported that calpain-2 activated Akt via the TGF-*β*1-mTORC2 pathway in pulmonary artery smooth muscle cells^[@bib101])^. However, patients suffering from idiopathic pulmonary arterial hypertension exhibited high plasma calpastatin levels^[@bib102])^. The hepatocyte-specific transduction of calpastatin reduced pulmonary calpain activity, resulting in the amelioration of murine hypoxia-induced pulmonary hypertension^[@bib102])^. Thus, reduced extracellular calpastatin levels as well as calpain activity in pulmonary arterioles may contribute to the pathogenesis of pulmonary hypertension.

Conclusive Remarks
==================

In conclusion, the dysregulation of calpain systems is responsible for a variety of degenerative vascular disorders (**[Fig. 2](#F2){ref-type="fig"}**), while these calpain systems are not substantially associated with vascular regulation under physiological conditions as well as vascular development. It is likely that the excessive activity of conventional calpains can induce these disorders, which are commonly caused by exogenous stressors, such as inflammatory cytokines and growth factors. Furthermore, loss of the endogenous inhibitor calpastatin potentiates calpain activity in some instances. In particular, it is noteworthy that the calpain-induced dysfunctional integrity of ECs and fibrogenic responses in VSMCs were reproduced by multiple studies (**[Table 1](#T1){ref-type="table"}**). In contrast to conventional isozymes, calpain-6 contributes to atherogenesis through its interference of mRNA splicing in macrophages. This indicates that calpain-6 might be associated with other macrophage-related diseases. Importantly, the loss-of-function of calpains almost uniformly ameliorates degenerative disorders. Indeed, the transgenic overexpression of calpastatin as well as calpain inhibitors such as MDL28170 and BDA-410, are effective treatments for degenerative disorders, suggesting that calpain inhibitors are potentially promising for the treatment of chronic vascular diseases. Candidate compounds for inhibiting conventional calpains are currently being tested in clinical trials including those of neurodegenerative diseases^[@bib14])^. These agents should be repositioned for cardiovascular fields in the future, while agents that inhibit calpain-6 are currently unavailable. The development of subtype selective inhibitors, in particular those targeting unconventional calpains, is indispensable for treating atherosclerosis and related diseases.

![Overview of the regulation of degenerative vascular disorders by calpain systems. LDL: low-density lipoprotein, EC: vascular endothelial cells, VSMCs: vascular smooth muscle cells, NF*κ*B: nuclear factor *κ*B, I*κ*B: inhibitor *κ*B, SOCS3: suppressor of cytokine signalling 3, JAK/STAT: Janus kinase/signal transducer and activator of transcription, NOS: nitric oxide synthase.](jat-25-1-g002){#F2}

###### Possible contribution of calpain systems in degenerative vascular disorders.

  Disease type                Experimental strategy                                                                                               Intervention                          Target molecule   Outcomes                               Ref.
  --------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------- ----------------- -------------------------------------- -----------
  Atherosclerosis             *Apoe*^−/−^ mice+high fat diet                                                                                      Calpeptin                             VE-cadherin       Atherosclerotic lesion↓                [@bib34]
                              *Ldlr*^−/−^ mice+high fat diet                                                                                      ALLM                                                    Aortic macrophage recruitment↓         
                                                                                                                                                                                                          Endothelial permeability↓              
                              Human umbilical vein endothelial cells+lysophosphatidylcholine                                                      *Capn2* siRNA                         VE-cadherin       Endothelial permeability↓              [@bib34]
                                                                                                                                                                                                          VE-cadherin proteolysis↓               
                              *Ldlr*^−/−^ mice+high fat diet                                                                                      *Capn6* ^−/−^                         CWC22             Atherosclerotic lesion↓                [@bib36]
                                                                                                                                                                                                          Aortic macrophage recruitment↓         
                                                                                                                                                                                                          Pinocytosis activity↓                  
                              Bone marrow-derived macrophages +TNF-*α*                                                                            *Capn6*^−/−^                          CWC22             Cellular motility↑                     [@bib36]
                                                                                                                                                                                                          Pinocytosis activity↓                  
                                                                                                                                                                                                          Rac1 activity↑                         
                                                                                                                                                                                                          Nuclear localization of CWC22↑         
                              *Ldlr*^−/−^ mice+high fat diet+AngII                                                                                BDA-410                               --                Atherosclerotic lesion↓                [@bib57]
                              *Ldlr*^−/−^ mice+high fat diet+AngII                                                                                *CAST*^+/*0*^ (myeloid specific)      --                Atherosclerotic lesion↓                [@bib58]
                                                                                                                                                  *Capn1*^−/−^ (myeloid specific)                                                                
                                                                                                                                                  *Capn2^flox/flox^/LysM-Cre*^+/*0*^                                                             
                              *Ldlr*^−/−^ mice+high fat diet                                                                                      *CAST*^+/*0*^                         --                Atherosclerotic lesion↓                [@bib58]
  Abdominal aortic aneurysm   *Ldlr*^−/−^ mice+high fat diet+AngII                                                                                BDA-410                               --                Abdominal aneurysm↓                    [@bib57]
                                                                                                                                                                                                          Aortic macrophage recruitment↓         
                                                                                                                                                                                                          MMP12↓                                 
                                                                                                                                                                                                          Proinflammatory genes↓                 
                              *Ldlr*^−/−^ mice+high fat diet+AngII                                                                                *CAST*^+/*0*^ (myeloid specific)      --                Abdominal aneurysm→                    [@bib58]
                                                                                                                                                  *Capn1*^−/−^ (myeloid specific)                         Aortic macrophage recruitment↓         
                                                                                                                                                  *Capn2^flox/flox^/LysMCre*^+/*0*^                                                              
                              Bone marrow-derived macrophages                                                                                     *CAST*^+/*0*^                         I*κ*B*α*          NF-*κ*B cascade↓                       [@bib58]
  Diabetic angiopathy         Zucker diabetic fatty rats (type 2 diabetes)                                                                        ZLLal                                 eNOS              NO production↑                         [@bib80]
                                                                                                                                                                                                          EC-leukocyte interaction↓              
                              Human umbilical vein endothelial cells+high glucose                                                                 Cast transduction                     --                Nitric oxide production↓               [@bib81]
                                                                                                                                                  MDL28170                                                ROS production↓                        
                              OVE26 type 1 diabetic mice                                                                                          *CAST*^+/*0*^                         --                Aortic ROS production↓                 [@bib81]
                                                                                                                                                                                                          EC-dependent vasodilation↑             
                              Hyperhomocysteinemic/diabetic mice (cystathionine *β*-synthasedeficient mice+high-methionine diet+streptozotocin)   MDL28170                              --                EC-dependent vasodilation↑             [@bib82]
                                                                                                                                                  Calpeptin                                               ROS production↓                        
                                                                                                                                                  ALLM                                                                                           
                              Human aortic endothelial cells                                                                                      MDL28170                              --                NO production↑                         [@bib82]
                                                                                                                                                  *CAPN1* siRNA                                           P-eNOS-pThr495↓                        
                              Streptozocin-induced diabetic mice                                                                                  A-705232                              PGI~2~ synthase   EC-dependent vasodilation↑             [@bib83]
                              Diabetic New Zealand obese mice                                                                                     Calpeptin                                               PGI~2~ synthesis↑                      
  Pathological angiogenesis   Oxygen-induced retinopathy model in mice                                                                            MDL 28170                             --                Oxygen-induced retinopathy↓            [@bib92]
                                                                                                                                                  PD150606                                                Retinal vascular permeability↓         
                                                                                                                                                  ALLN                                                                                           
                              Oxygen-induced retinopathy model in mice                                                                            *LNL-CAST*^+/*0*^/*Tie2-Cre*^+/*0*^   SOCS3             Tumor angiogenesis↓                    [@bib35]
                                                                                                                                                                                                          Oxygen-induced retinopathy↓            
                              Tumor implantation in mice                                                                                                                                                  VEGF-C production↓                     
                                                                                                                                                                                                          Maturation of neovessels↑              
                              Human aortic endothelial cells+ IL-6                                                                                *Cast* siRNA                          SOCS3             Migration↑                             [@bib35]
                                                                                                                                                                                                          Proliferation↑                         
                                                                                                                                                                                                          Tube formation↑                        
                                                                                                                                                                                                          JAK/STAT3 signal↑                      
                                                                                                                                                                                                          VEGF-C production↑                     
                              Co-culture B16 melanoma cells with ECs                                                                              MDL28170                              Vasohibin-1       Vasohibin-1 proteolysis↓               [@bib34]
  Age-associated fibrosis     AngII-induced aortic hypertrophy model                                                                              *CAST*^+/*0*^                         --                Aortic fibrosis↓                       [@bib95]
                                                                                                                                                                                                          Aortic hypertrophy↓                    
                                                                                                                                                                                                          Perivascular leukocyte recruitment↓    
                                                                                                                                                                                                          NF-*κ*B cascade↓                       
                              Primary VSMCs from aged rats+ AngII                                                                                 Calpain inhibitor I                   --                MMP2 activity↓                         [@bib19]
                                                                                                                                                  *CAST* transduction                                     VSMC migration↓                        
                              Primary VSMCs from aged rats                                                                                        *CAPN1* transduction                  --                Fibrosis↑                              [@bib96]
                              Cultured carotid artery rings                                                                                                                                               Calcification↑                         
                                                                                                                                                                                                          Smad1/2↑                               
                                                                                                                                                                                                          TGF-*β*1↑                              
                                                                                                                                                                                                          Osteopontin↓                           
                                                                                                                                                                                                          Osteonectin↓                           
  Arterial restenosis         Carotid artery ligation model in mice                                                                               *CAST*^+/*0*^                         --                Arterial restenosis↓                   [@bib97]
                                                                                                                                                                                                          Arterial fibrosis↓                     
                                                                                                                                                                                                          Arterial hypertrophy↓                  
                                                                                                                                                                                                          Arterial MMP2/TGF-^β^1↓                
                              Primary VSMCs from mice+ PDGF-BB                                                                                    *Capn1* siRNA                         --                Proliferation↓                         [@bib97]
                                                                                                                                                  *Capn2* siRNA                                           Migration↓                             
  Pulmonary hypertension      Chronic hypoxia-induced pulmonary hypertension model in mice                                                        *Capn2^flox/flox^/ER-Cre*^+/*0*^      TGF-*β*1          Pulmonary hypertension↓                [@bib100]
                                                                                                                                                                                                          Collagen I in pulmonary arterioles↓    
                                                                                                                                                                                                          Hypertrophy in pulmonary arterioles↓   
                              Monocrotaline-induced pulmonary hypertension model in rats                                                          MDL28170                              --                Pulmonary hypertension↓                [@bib100]
                                                                                                                                                                                                          Hypertrophy in pulmonary arterioles↓   
                              Human pulmonary arterial smooth muscle cells+PDGF-BB                                                                MDL28170                              TGF-*β*1          Collagen I synthesis↓                  [@bib100]
                                                                                                                                                  *Capn1* siRNA                                           Proliferation↓                         
                                                                                                                                                  *Capn2* siRNA                                           TGF-*β*1 production↓                   
                              Chronic hypoxia-induced pulmonary hypertension model in mice                                                        *Capn2^flox/flox^/ER-Cre*^+/*0*^      --                P-Akt-S473 in pulmonary arterioles↓    [@bib101]
                                                                                                                                                                                                          P-Akt-T308 in pulmonary arterioles↓    
                              Human pulmonary arterial smooth muscle cells+PDGF-BB                                                                MDL28170                              --                Collagen I synthesis↓                  [@bib101]
                                                                                                                                                  *Capn2* siRNA                                           Proliferation↓                         
                                                                                                                                                                                                          P-Akt-S473↓                            
                                                                                                                                                                                                          P-Akt-T308↓                            
                              Murine hypoxia-induced pulmonary hypertension model                                                                 *CAST* transduction (CMV promoter)    --                Pulmonary hypertension↓                [@bib102]
                                                                                                                                                                                                          Hypertrophy in pulmonary arterioles↓   
                              SM22-5HTT1 mice                                                                                                     *CAST* transduction (CRP promoter)                                                             
                                                                                                                                                  PD150606                                                                                       
                              Murine pulmonary arterial smooth muscle cells+FBS, +PDGF-BB, +EGF                                                   PD150606                              --                Proliferation↓                         [@bib102]
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